Nuvation Bio, Inc. (NUVB)
| Market Cap | 2.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.28M |
| Shares Out | 216.65M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $11.55 |
| Previous Close | $11.02 |
| Change ($) | 0.53 |
| Change (%) | 4.81% |
| Day's Open | 11.02 |
| Day's Range | 11.02 - 11.60 |
| Day's Volume | 364,944 |
| 52-Week Range | 8.56 - 15.07 |
SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,...
SAN FRANCISCO--(BUSINESS WIRE)--Panacea Acquisition Corp., a Delaware corporation (the “Company”) (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333...
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: P...
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PAR... [Read more...]
| Industry Biotechnology | Founded 2018 |
| Stock Exchange NYSE | Ticker Symbol NUVB |
Analyst Forecasts
The average 12-month stock price forecast for Nuvation Bio is 17.60, which is an increase of 52.38% from the latest price.